Inadequate treatment of congestive heart failure in dialysis patients

Seminars in Dialysis

Volumn 20, Issue 5, 2007, Pages 383-386

  Bouchard, Josée ^a   Madore, François ^a  

^a HÔPITAL DU SACRÉ COEUR DE MONTRÉAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR;

ARTICLE; CHRONIC KIDNEY FAILURE; CONGESTIVE HEART FAILURE; DIALYSIS; HUMAN; PRESCRIPTION; STANDARD; TREATMENT FAILURE;

ADRENERGIC BETA-ANTAGONISTS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; DIALYSIS; HEART FAILURE, CONGESTIVE; HUMANS; KIDNEY FAILURE, CHRONIC; PRESCRIPTIONS, DRUG; TREATMENT FAILURE;

EID: 34748823525     PISSN: 08940959     EISSN: 1525139X     Source Type: Journal    
DOI: 10.1111/j.1525-139X.2007.00313.x     Document Type: Article

References (29)

1. Stack AG, Bloembergen WE : A cross-sectional study of the prevalence and clinical correlates of congestive heart failure among incident US dialysis patients. Am J Kidney Dis 38 : 992 1000, 2001
2. Trespalacios FC, Taylor AJ, Agodoa LY, Bakris GL, Abbott KC : Heart failure as a cause for hospitalization in chronic dialysis patients. Am J Kidney Dis 41 : 1267 1277, 2003
3. Harnett JD, Foley RN, Kent GM, Barre PE, Murray D, Parfrey PS : Congestive heart failure in dialysis patients: prevalence, incidence, prognosis and risk factors. Kidney Int 47 : 884 890, 1995
4. Roy P, Bouchard J, Amyot R, Madore F : Prescription patterns of pharmacological agents for left ventricular systolic dysfunction among hemodialysis patients. Am J Kidney Dis 48 : 645 651, 2006
5. Cice G, Ferrara L, D'Andrea A, D'Isa S, Di Benedetto A, Cittadini A, Russo PE, Golino P, Calabro R : Carvedilol increases two-year survival in dialysis patients with dilated cardiomyopathy: a prospective, placebo-controlled trial. J Am Coll Cardiol 41 : 1438 1444, 2003
6. Efrati S, Zaidenstein R, Dishy V, Beberashvili I, Sharist M, Averbukh Z, Golik A, Weissgarten J : ACE inhibitors and survival of hemodialysis patients. Am J Kidney Dis 40 : 1023 1029, 2002
7. Guerin AP, Blacher J, Pannier B, Marchais SJ, Safar ME, London GM : Impact of aortic stiffness attenuation on survival of patients in end-stage renal failure. Circulation 103 : 987 992, 2001
8. Stoves J, Baczkowski A, Turney J : Factors influencing survival of diabetic patients after initiation of renal replacement therapy. Nephrology 6 : 79 84, 2001
9. Zannad F, Kessler M, Lehert P, Grunfeld JP, Thuilliez C, Leizorovicz A, Lechat P : Prevention of cardiovascular events in end-stage renal disease: results of a randomized trial of fosinopril and implications for future studies. Kidney Int 70 : 1318 1324, 2006
10. Foley RN, Herzog CA, Collins AJ : Blood pressure and long-term mortality in United States hemodialysis patients: USRDS Waves 3 and 4 Study. Kidney Int 62 : 1784 1790, 2002
11. Hara Y, Hamada M, Shigematsu Y, Murakami B, Hiwada K : Beneficial effect of beta-adrenergic blockade on left ventricular function in haemodialysis patients. Clin Sci (Lond) 101 : 219 225, 2001
12. Abbott KC, Trespalacios FC, Agodoa LY, Taylor AJ, Bakris GL : Beta-Blocker use in long-term dialysis patients: association with hospitalized heart failure and mortality. Arch Intern Med 164 : 2465 2471, 2004
13. Takahashi A, Takase H, Toriyama T, Sugiura T, Kurita Y, Ueda R, Dohi Y : Candesartan, an angiotensin II type-1 receptor blocker, reduces cardiovascular events in patients on chronic haemodialysis-a randomized study. Nephrol Dial Transplant 21 : 2507 2512, 2006
14. Hunt SA : ACC/AHA 2005 guideline update for the diagnosis and management of chronic heart failure in the adult: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure). J Am Coll Cardiol 46 : e1 e82, 2005
15. Krum H, Haas SJ, Eichhorn E, Ghali J, Gilbert E, Lechat P, Packer M, Roecker E, Verkenne P, Wedel H, Wikstrand J : Prognostic benefit of beta-blockers in patients not receiving ACE-Inhibitors. Eur Heart J 26 : 2154 2158, 2005
16. Arnold JM, Liu P, Demers C, Dorian P, Giannetti N, Haddad H, Heckman GA, Howlett JG, Ignaszewski A, Johnstone DE, Jong P, McKelvie RS, Moe GW, Parker JD, Rao V, Ross HJ, Sequeira EJ, Svendsen AM, Teo K, Tsuyuki RT, White M : Canadian Cardiovascular Society consensus conference recommendations on heart failure 2006:diagnosis and management. Can J Cardiol 22 : 23 45, 2006
17. K/DOQI : Clinical practice guidelines for cardiovascular disease in dialysis patients. Am J Kidney Dis 45 : S1 S153, 2005
18. Robson R, Collins J, Johnson R, Kitching R, Searle M, Walker R, Douglas J, Leary J, Whalley G, Sharpe N, MacMahon S : Effects of simvastatin and enalapril on serum lipoprotein concentrations and left ventricular mass in patients on dialysis. The Perfect Study Collaborative Group. J Nephrol 10 : 33 40, 1997
19. Agarwal R, Lewis R, Davis JL, Becker B : Lisinopril therapy for hemodialysis hypertension: hemodynamic and endocrine responses. Am J Kidney Dis 38 : 1245 1250, 2001
20. Knoll GA, Sahgal A, Nair RC, Graham J, van Walraven C, Burns KD : Renin-angiotensin system blockade and the risk of hyperkalemia in chronic hemodialysis patients. Am J Med 112 : 110 114, 2002
21. Han SW, Won YW, Yi JH, Kim HJ : No impact of hyperkalaemia with renin-angiotensin system blockades in maintenance haemodialysis patients. Nephrol Dial Transplant 22 : 1150 1155, 2007
22. Nowicki M, Miszczak-Kuban J : Nonselective Beta-adrenergic blockade augments fasting hyperkalemia in hemodialysis patients. Nephron 91 : 222 227, 2002
23. Nowicki M, Szewczyk-Seifert G, Klimek D, Kokot F : Carvedilol does not modulate moderate exercise-induced hyperkalemia in hemodialysis patients. Clin Nephrol 57 : 352 358, 2002
24. Agarwal R : Supervised atenolol therapy in the management of hemodialysis hypertension. Kidney Int 55 : 1528 1535, 1999
25. Covic A, Gusbeth-Tatomir P, Goldsmith DJ : Is it time for spironolactone therapy in dialysis patients? Nephrol Dial Transplant 21 : 854 858, 2006
26. Saudan P, Mach F, Perneger T, Schnetzler B, Stoermann C, Fumeaux Z, Rossier M, Martin PY : Safety of low-dose spironolactone administration in chronic haemodialysis patients. Nephrol Dial Transplant 18 : 2359 2363, 2003
27. Gross E, Rothstein M, Dombek S, Juknis HI : Effect of spironolactone on blood pressure and the renin-angiotensin-aldosterone system in oligo-anuric hemodialysis patients. Am J Kidney Dis 46 : 94 101, 2005
28. Hussain S, Dreyfus DE, Marcus RJ, Biederman RW, McGill RL : Is spironolactone safe for dialysis patients? Nephrol Dial Transplant 18 : 2364 2368, 2003
29. Loghman-Adham M : Medication noncompliance in patients with chronic disease: issues in dialysis and renal transplantation. Am J Manag Care 9 : 155 171, 2003